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Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is associated with an abnormal pulmonary and
systemic immune response to tobacco smoking. Yet, how do immune cells relate within and between these two
biological compartments, how the pulmonary infiltrate influences the lung transcriptome, and what is the role of
active smoking vs. presence of disease is unclear.
Methods: To investigate these questions, we simultaneously collected lung tissue and blood from 65 individuals
stratified by smoking habit and presence of the disease. The immune cell composition of both tissues was assessed
by flow cytometry, whole lung transcriptome was determined with Affymetrix arrays, and we used Weighted Gene
Co-expression Network Analysis (WGCNA) to integrate results.
Results: Main results showed that: (1) current smoking and the presence of COPD were both independently
associated with a reduction in the proportion of lung T cells and an increase of macrophages, specifically
those expressing CD80 + CD163+; (2) changes in the proportion of infiltrating macrophages, smoking status or
the level of airflow limitation were associated to different WGCNA modules, which were enriched in iron ion
transport, extracellular matrix and cilium organization gene ontologies; and, (3) circulating white blood cells
counts were correlated with lung macrophages and T cells.
Conclusions: Mild-moderated COPD lung immune infiltrate is associated with the active smoking status and
presence of disease; is associated with changes in whole lung tissue transcriptome and marginally reflected in
blood.
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Background
Tobacco smoking is the main environmental risk factor
for COPD, albeit not all smokers develop the disease [1,
2]. It is currently accepted that, in so-called “susceptible
smokers”, tobacco smoking triggers an abnormal pulmon-
ary and systemic immune response that eventually dam-
ages the lung parenchyma and leads to persistent airflow
limitation and COPD [1–5]. Yet, some aspects of this
pathogenic paradigm are still unclear and require specific
research. For instance, although in cross-sectional studies
[6–9] the number of inflammatory cells infiltrating the
lung parenchyma increase in parallel with the severity of
airflow limitation, how do these cells relate among them-
selves is unknown. Likewise, it is unclear how changes in
the pulmonary immune cell network relate to changes in
the whole lung transcriptome [10–13]. Besides, given that
smoking per se has well recognized effects on the im-
mune system [4, 14], it is important (and challenging)
to disentangle the role of disease itself vs. that of active
smoking. Finally, previous studies have tried to identify
blood surrogate markers of lung changes [15, 16], but
the relation between different immune cell types in the
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two compartments (i.e. lung and blood) has not been
ever assessed.
We hypothesized that a data set that combined lung
tissue and circulating blood measurements collected
simultaneously in current and former smokers with
COPD, as well as controls with normal lung function
(current and never smokers), would be a unique asset
to: (1) characterize the lung and blood immune cell
composition in relation to both smoking status and
presence of disease; (2) explore the relationship be-
tween the lung immune cell composition and the
lung tissue transcriptome; and, finally, (3) construct a
multi-level (lung and blood) immune cell correlation
network to assess if the lung changes are reflected in
the blood.
Methods
Full methods are provided in the Additional file 1.
Population and ethics
We prospectively collected clinically relevant informa-
tion as well as lung tissue and blood samples from 65
patients who required thoracic surgery for lung cancer
(Table 1). The lung tissue was from a non-affected loca-
tion. All participants signed their informed consent, and
the Ethics Committee of our institution approved the
study (HCB-2012/7731).
Lung tissue processing
Fresh lung tissue was washed with PBS, enzymatically
digested with 0.5 mg/ml Collagenase P and 0.1 mg/ml
DNase I (Roche, Germany), incubated at 37 °C for 30
min, and mechanically digested with GentleMACS M-
dissociator tubes (Miltenyi Biotech, Germany).
Measurements
Lung function
Forced spirometry and carbon monoxide lung capacity
(DLCO) were determined according to international rec-
ommendations [2] and reference values corresponded to
a Mediterranean population [17].
Circulating inflammatory markers
Circulating venous blood was collected in EDTA tubes
(BD, US) in the operating room before surgery started.
Total white blood cells counts were quantified with an
ADVIA-2120 system (Siemens, Germany). The plasma
concentration of high sensitivity C Reactive Protein
(hsCRP) was determined by ultra-sensitive quantitative
turbidimetric test (Bayer Diagnostics, Germany).
Flow cytometry
Immune cell populations were analysed in parallel in
blood and lung tissue. Lung tissue homogenates (5·105
cells) or 50 μl of peripheral blood were stained with the
corresponding fluorescently conjugate monoclonal anti-
body mix (Additional file 1: Table S1), incubated at 4 °C
for 30 min and washed. A minimum of 2·105 cells per
tube were acquired in a FacsCanto (BD Biosciences, US),
data was analyzed using FlowJo v10 software (FlowJo
LLC, US) Additional file 2: Figures S1-S6.
Transcriptomic analysis
Total RNA was isolated with PureLink RNA-MiniKit (Life
Technologies, US), quantified by Nanodrop (Thermo Sci-
entific, Germany). RNA samples with integrity numbers
(RIN) ≥ 7 (Agilent technologies, Germany), where ana-
lysed with the Affymetrix GeneChip® Human Genome
U219 Array Plate. Only from 53 individuals the mRNA
quality was adequate for analysis (Additional file 1: Table
Table 1 Clinical variables of the subjects enrolled in the analysis of the cellular immune response
Non-Smokers Smokers COPD-FS COPD-CS P
valuen = 12 n = 9 n = 16 n = 28
Age (years) 67.6 ± 9.5 58.0 ± 9.3 64.5 ± 8.1 67.8 ± 7.8 0.0587
Gender (M/F) 3/9 5/4 14/2 20/8 0.0051
Pack/year – 36.8 ± 19.1 48.7 ± 19.9 51.1 ± 22.1 0.1830
BMI (Kg/m2) 28.0 ± 6.7 27.4 ± 5.4 24.9 ± 3.8 28.0 ± 3.5 0.0974
FEV1/FVC (%) 77.9 ± 4.1 79.1 ± 10.1 61.7 ± 6.5 59.9 ± 7.1 0.0000
FEV1 (% ref) 97.3 ± 8.1 95.1 ± 7.5 77.1 ± 13.0 77.3 ± 18.3 0.0001
DLCO (% ref.) 78.3 ± 16.2 78.9 ± 11.4 61.6 ± 9.6 71.4 ± 14.7 0.0021
WBC 10^9/L 7.5 ± 2.1 9.3 ± 4.01 6.5 ± 2.2 8.6 ± 2. 2 0.0193
Abs Neutrophil count (10^9/L) 5.0 ± 2.1 6.1 ± 4.0 4.0 ± 1.6 5.5 ± 1.8 0.0448
hsCRP mg/dl 0.72 ± 0.96 8.56 ± 18.09 0.62 ± 0.98 2.43 ± 4.94 0.0954
FS Former smokers, CS Current smokers, WBC white blood cell count, hsCRP high sensitivity C Reactive Protein, BMI Body Mass Index, FEV 1 Forced expiratory
volume 1 s, FVC forced vital capacity
P value of the kruskall wallis or chi square test
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S2). Raw microarray data has been deposited in GEO
(GSE103174).
Data analysis
Statistical analysis were performed using R [18]. Results
are presented as n, proportion, or mean ± standard de-
viation. Differences between groups were assessed using
the Kruskal-Wallis test, followed by post-hoc contrasts
if necessary (Table 2). A linear model after log trans-
formation of variables was used to ascertain the inde-
pendent contribution of smoking status and presence
of disease. P values < 0.05 were considered significant.
Lung-blood immune cell correlation networks were
built with R and visualized using Cytoscape as de-
scribed elsewhere (Spearman coefficient r > |0.3| and a
p-value < 0.05) [19].
Results
Participant characteristics
Table 1 presents the main characteristics of participants.
In patients with COPD the proportion of subjects with
GOLD grade 1 airflow limitation (31% (n = 5) vs. 32%
(n = 9)) and GOLD grade 2 (69% (n = 11) vs. 68% (n =
19)) was similar in former (FS) and current smokers
(CS) patients, respectively. DLCO was mildly reduced in
COPD patients. Circulating leukocyte and neutrophil
counts and hsCRP plasma levels were increased in
current smokers (with or without COPD) (Table 1).
Characterization of lung and blood immune cells
Figure 1 (panels a and b) compares the proportion of the
different lung immune cell populations studied, expressed
as percentage of total CD45+ cells (hematopoietic lineage, a
common practice in order to perform immunophenotyping
in non-lymphoid tissues [20]) in the four groups investi-
gated. Main differences were observed in current smokers
with COPD (COPD-CS) who showed: (1) a significant re-
duction in the proportion of T-cells that involved both
CD4+ and CD8+ T cells (Table 2 and Additional file 2: Fig-
ure S7); (2) a significant increase in the proportion of mac-
rophages (Mϕ) (Fig. 1a), of whom a higher percentage
expressed both CD80 +CD163+ (Table 2, Additional file 2:
Figure S8) and a relative reduction of CD80 +CD163-Mϕ
(Table 2, Additional file 2: Figure S8); and, (3) a different
distribution of lung monocytes between study groups
(Fig. 1b) due to an increase of monocytes in COPD-CS
(Table 2, Additional file 2: Figure S8D).
As main changes were observed in COPD-CS, next we
used a linear model in order to evaluate if both current
smoking and presence of COPD have an independent ef-
fect. We observed that current smoking was inversely
related to the proportion of lung T-lymphocytes (βeta =
− 0.111, p value =0.008) and positively with that of mac-
rophages (Mϕ) (βeta =0.210, p value =0.001) and mono-
cytes (βeta =0.104, p value =0.005); while the presence of
COPD had an independent but smaller effect (Mϕ, βeta
=0.152, p value =0.05; T-lymphocytes, βeta = − 0.100, p
value =0.065).
Finally, the proportion of the different immune cell
populations in circulating blood was not different across
groups (Fig. 1c and d).
Relationship between lung immune cell population and
whole lung transcriptome
To assess the association between the immune composition
of the lung and the biological processes on-going in the
lung, we measured the gene expression profile of the whole
lung from 53 participants (82% of the total population stud-
ied, Additional file 1: Table S2) and used Weighted Gene
Co-expression Network Analysis (WGCNA) to integrate
the information. WGCNA defines a set of modules of co-
expressed genes, and for each provides their “eigengene”
value (i.e., the principal component of the expression
matrix of the probes within the module). The eigengene
can be related to the variables of interest [21], in our case
FEV1, the smoking status and the percentage of lung mac-
rophages (the cell population reporting more differences
across study groups).
Table 2 Post-hoc analysis on lung cell populations reported as
% of CD45 gated cells
Cell population Group 1 Group 2 P value (Mann-Whitney)
% Mϕ CS-COPD FS-COPD 0.004
% Mϕ CS-COPD NS 0.005
% Monocytes CS-COPD FS-COPD 0.015
% Monocytes CS-COPD NS 0.009
% T cells CS-COPD FS-COPD 0.002
% T cells CS-COPD NS 0.006
% T cells CS-COPD S 0.024
% T CD4+ CS-COPD FS-COPD 0.008
% T CD8+ CS-COPD S 0.035
% T CD8+ CS-COPD NS 0.046
% Mϕ CD80+ CD163- CS-COPD FS-COPD 0.055
% Mϕ CD80+ CD163- CS-COPD NS 0.040
% Mϕ CD80+ CD163- S NS 0.036
% Mϕ CD80+ CD163- FS-COPD S 0.019
% Mϕ CD80 + CD163+ CS-COPD FS-COPD 0.000
% Mϕ CD80 + CD163+ CS-COPD NS 0.000
On populations that showed a significantly different distribution between the
4 study groups (Fig. 1 and Additional file 2: Figures S7-S8) a post-hoc analysis
was performed using the Mann-Whitney on original values
NS non-smoker, S normal lung function smoker, FS-COPD Former smoker with
COPD, CS-COPD Current Smoker with COPD
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WGCNA identified 23 modules (Additional file 1:
Table S3), of them in eight the eigengene was signifi-
cantly associated with the variables of interest (Fig. 2).
Specifically, we observed that one module (Yellow, n =
645 genes) was associated to the levels of FEV1 and DLCO
% predicted. (Fig. 3) and was enriched in genes associated
to the Cilium Organization Gene Ontology biological
process term (GO) (Additional file 1: Tables S4-S5).
Three modules were associated both to the smoking sta-
tus and percentage of infiltrating Mϕ (Fig. 3): (i) Tan (n =
211), enriched for iron metabolism and phospholipid me-
tabolism GO terms (Additional file 1: Tables S4-S5), (iii)
Royalblue (n = 86), related to T cell activation GO terms
(Additional file 1: Tables S4-S5), (iii) Lightcyan (n = 140),
related to mRNA processing GO terms (Additional file 1:
Tables S4-S5).
Three modules were associated to the level of lung Mϕ
expressing different surface markers (Fig. 2 and Add-
itional file 2: Figure S9): i) Greenyellow (n = 227), especially
related to CD80 + CD163+ Mϕ, with genes enriched in
extracellular matrix organization and collagen metabolism
GO terms (Additional file 1: Tables S4-S5). Interestingly
this module also presented a negative correlation with the
levels of DLCO % ref. (ii) Blue (n = 789), related to CD80-
CD163+ Mϕ, with genes enriched in ER to Golgi vesicle
transport and regulation of translation GO terms (S4-S5).
(iii) LightCyan (n = 140), related to CD80-CD163+ Mϕ,
with genes enriched in mRNA processing (S4-S5).
Finally, we assessed which of the module genes have
been previously identified as differentially expressed in
lung tissue of COPD (GSE47460). The 10 genes with high-
est differential expression (DE) included are reported in
a b
c d
Fig. 1 Proportion of immune cell populations (mean ± SD), expressed as percentage of total CD45+ cells, both in lung tissue (Top panels a and
b) and circulating blood (Bottom panels c and d). Study groups: never smokers (white bars), smokers with normal lung function (grey bars),
COPD-former smokers (COPD-FS, gray stripped bars) and COPD current smokers (COPD-CS, black bars). Note the different Y scales in right vs. left
panels. For further explanations, see text
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Table 3. Interestingly, the modules including more differ-
entially expressed genes were the GreenYellow (n = 50)
and the Yellow (n = 25) (Additional file 1: Table S6).
Multi-level (blood and lung) immune cell correlation
network
Finally, we build a multi-level correlation network
[22] to investigate the potential relationships between
immune cells and clinical variables in both lung and
blood (Fig. 3) and observed that: (1) the strongest
correlations were found between cells of the same tis-
sue (percentage of lung Mϕ and T cells (r = − 0.81)
and percentage of blood T cells and neutrophils (r =
− 0.73); (2) eight of the 40 total connections (20%) in-
volved lung and blood populations (Fig. 2, highlighted
with blue edges). Of note, that the percentage of lung
T cells was related to the percentage of blood T cells
(r = 0.34), and the absolute counts of leukocytes (r = −
0.33). Interestingly, the absolute counts of blood leu-
kocytes was also positively correlated with the propor-
tion of lung Mϕ (r = 0.3); (3) FEV1% predicted was
positively correlated with the proportion of lung T
cells as well as lung and blood NKT cells, whereas it
was negatively correlated with the proportion of lung
DCs; and, finally (4) Carbon monoxide lung diffusing
capacity (DLCO, % ref.), a well-validated surrogate
marker of emphysema [23], was negatively correlated
with the proportion of lung Mϕ, DCs and Monocytes,
and positively correlated with those of lung T cells
and peripheral blood T cells. It is of note that clinical
variables were mostly correlated with lung tissue (not
blood) populations (Fig. 3).
Discussion
The main and novel observations of this study are that: (1)
the composition of the immune cell infiltrate in the lung
(but not in circulating blood) is significantly altered by ac-
tive smoking and the presence of mild-moderate COPD.
These changes are characterized by a reduction in the pro-
portion of lung CD4+ and CD8+ T lymphocytes, and an in-
crease in that of Mϕ, especially those expressing CD80 and
CD163; (2) the percentage of lung tissue Mϕ is associated,
independently of the airflow limitation and smoking status,
to several modules of co-expressed genes in whole lung
Fig. 2 Heat-map of module association with: the level of FEV1% predicted, the smoking status, and the percentage of Macrophages (Mϕ)). The
top number in each cell corresponds to the effect from the linear regression and the bottom number is the p-value. In the box, the summarizing
terms for the Gene Ontology (GO) terms significantly enriched for this module obtained from the Revigo analysis are displayed. The full list of GO
terms if provided in Additional file 1: Table S5. For further explanations, see text
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Fig. 3 Multilevel (lung and blood) Spearman correlation network (|r| > 0.3, p < 0.05) for all participants (n = 65) of lung (green), peripheral blood
(red) immune cell populations, lung function variables (blue) and general systemic inflamatory biomarkers (yellow). Positive correlations are
represented with a continuous edge while the negatives are with a discontinuous edge. Edge witdth is proportional to the strength of the
correlation. Node size is proportional to the mean percentatge of CD45% cells of the population. Blue links are used to highlight correlations
between lung and blood markers. For further explanations, see text
Table 3 Top Genes differentially expressed in Controls vs. COPD in the LTRC consortium dataset
Module symbol adj.P.Val logFC Module symbol adj.P.Val logFC
1 Yellow FGG 5.54E-06 −1.92 1 Yellow KRT4 2.10E-06 0.93
2 Greenyellow PLA2G2A 2.21E-03 −1.03 2 Yellow SLITRK6 1.76E-04 0.76
3 Blue BNC1 9.91E-04 −0.99 3 Yellow CDHR3 2.57E-02 0.70
4 Greenyellow POU2AF1 6.61E-05 −0.93 4 Yellow CFAP74 3.68E-02 0.60
5 Greenyellow MZB1 1.96E-04 −0.84 5 Yellow TNNI3 1.86E-03 0.56
6 Greenyellow TNFRSF17 7.95E-04 −0.76 6 Yellow SEC14L4 7.42E-05 0.55
7 Greenyellow IGDCC4 4.07E-05 −0.68 7 Blue PRPH 9.61E-06 0.54
8 Greenyellow CPXM1 3.28E-03 −0.68 8 Yellow SEC14L3 4.30E-02 0.53
9 Greenyellow COL14A1 5.88E-05 −0.64 9 Yellow PRMT8 1.07E-02 0.51
10 Greenyellow CTHRC1 1.50E-03 −0.61 10 Yellow VWA3A 3.99E-02 0.46
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tissue including genes that have been previously associated
with the pathobiology of COPD; and, finally (3) the im-
mune cell multi-level correlation network shows some
weak relations between lung and blood cells, the strongest
one between the absolute number of blood leukocytes and
the proportion of lung macrophages and T cells.
Many previous studies have investigated the pulmonary
and systemic inflammatory response in COPD [6–8]. It is
generally accepted that the absolute number of T-cells,
both CD8+ cytotoxic T lymphocytes [24] and CD4+ T
lymphocytes (polarized towards a TH1 response) [25], in-
crease in patients with severe-very severe COPD. Our re-
sults in lung tissue show a reduction in the proportion of
infiltrating T cells which was mostly related to smoking
and only marginally to the presence of COPD. Apparently,
therefore, our results do not agree with previous reports.
However, to interpret them appropriately, it is important
to consider that: (1) because our methodology does not
allow the quantification of the absolute number of infil-
trating cells, our results refer to their relative proportion
(not to their absolute numbers); (2) we studied patients
with mild-moderate, not severe-very severe, COPD. In
fact, a recent study in bronchoalveolar lavage fluid (BALF)
obtained from patients with mild-moderate COPD
(GOLD grades 1–2) also reported a decrease in the pro-
portion of T CD4+ cells and a clear effect of active smok-
ing on cell population distribution [26]. This is indeed in
line with our results and highlighting that GOLD grade
and current smoking have both to be carefully considered
when investigating the inflammatory response of COPD.
On the other hand, it is well established that Mϕ are in-
creased in BALF and lung tissue of COPD patients [27].
Our results are in keeping with these previous observa-
tions and extend them by showing that this increase is re-
lated independently both to active smoking and, to a
lesser extent, to the presence of the disease.
Several previous studies have investigated lung tran-
scriptomics in COPD [28, 29], but to our knowledge none
has previously related the transcriptomic status with the
proportion of infiltrating macrophages. Using WGCNA
we identified four transcriptomic co-expression modules
that were associated with the proportion of lung Mϕ inde-
pendently of the level of airflow limitation and smoking
status. Interestingly one module (GreenYellow) was associ-
ated with the percentage of CD80 + CD163+ macrophages
and enriched in ontologies related to extracellular matrix
organization and collagen metabolism. Interestingly this
module presented a negative correlation with the levels of
DLCO, in agreement with the findings of the multi-level
correlation network. This module included genes differen-
tially expressed in other lung tissue cohorts as: COL14A1,
SFRP2 and CCDC80. Several reports have identified a dif-
ferential expression of collagen genes in COPD [10], while
SFRP2 has been related to a down-regulation of the WNT
pathway and CCDC80 is expressed by alveolar macro-
phages [30]. Although this is a starting point for future
research aimed at understanding mechanistically the
pathogenic relevance of these associations, is in line
with our previous reports of an abnormal catabasis in
lung tissue macrophages of patients with COPD [31].
Finally, previous studies reported alterations in specific
subsets of circulating blood cells, specifically an increase
in total leukocytes and neutrophils in relation to current
smoking has been described [5, 32]. But none used net-
work analysis to relate lung and blood immune cells
with clinical characteristics. Our results showed that cir-
culating white cells (both total leukocyte counts) were
negatively correlated with the percentage of lung T-cells
and positively correlated with the percentage of lung
Mϕ. Yet, the overall relation between the two compart-
ments (lung and blood) is weak, so the blood immune
cell composition cannot be used to predict the inflam-
matory status of the lung tissue.
The strengths of the study are that, for the first time it
profiles a wide variety of immune cells, both in lung tis-
sue and circulating blood, of a relatively large population
of patients with mild moderated COPD and controls
and uses multi-level network analysis to relate the im-
mune response of the pulmonary and systemic compart-
ments. Likewise, it is the first to investigate the lung
transcriptome with the immune cell infiltrate. On the
other hand, the limitations of the study are that all par-
ticipants had surgically resectable lung cancer and that,
although analysed lung samples were tumor-free, this
can be a potentially confounding factor in our analysis.
However, if this was the case, it might have affected
similarly all samples analysed. Finally, it would have been
interesting to assess how the immune infiltrate changes
according to both current smoking and inhaled cortico-
steroid treatment (ICS) treatment, yet our cohort is
underpowered to do these analysis as only COPD 8 pa-
tients were under ICS treatment.
Conclusions
This study, by integrating high throughput analytical tech-
niques in a unique, multi-level data set, provides novel in-
formation on the relation of the pulmonary and systemic
inflammatory response that characterizes COPD. Our
main findings highlight the role of lung macrophages and
the active smoking status in the pathobiology of COPD.
All in all, these observations contribute to a better under-
standing of COPD pathobiology.
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